The lifetime of substance use disorders in schizophrenia is close to 50%. Substance abuse in schizophrenia is associated with negative consequences. Unfortunately, there no clear guidelines for the pharmacological treatment of this dual diagnosis population. Preliminary results suggest that second-generation antipsychotic drugs (mainly clozapine) may relieve drug cravings in schizophrenia. We...
Date First Received: February 21, 2006
Last Updated: February 21, 2006
Verified by: University of Montreal, September 2005
Clinical Trial Phase: Phase 4 | Start Date:
Overall Status: Completed
Brief Summary
Official Title: “The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients”
Condition Keyword(s):
Intervention(s):
The lifetime of substance use disorders in schizophrenia is close to 50%. Substance abuse in schizophrenia is associated with negative consequences. Unfortunately, there no clear guidelines for the pharmacological treatment of this dual diagnosis population. Preliminary results suggest that second-generation antipsychotic drugs (mainly clozapine) may relieve drug cravings in schizophrenia. We performed a 12-week pilot study to evaluate the impact of quetiapine, a second-generation antipsychotic, on substance abuse parameters, psychiatric symptoms and side effects in patients schizophrenia and comorbid substance use disorders. Our expectation was a 20 % decrease in drug cravings from baseline to end-point.
Study Type: Interventional
Study Design: Non-Randomized, Open Label, Uncontrolled, Single Group Assignment
Intervention(s) in this Clinical Trial
- Drug: quetiapine (drug)
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Patients with as schizophrenia spectrum disorder
- Patients with a comorbid substance use disorder
Exclusion Criteria:
- Patients already on quetiapine or clozapine
- Patients hospitalized or acutely ill
- Total score lower than 65 on the PANSS
- Pregnancy
- Female subjects of childbearing potential without adequate contraception
- Abnormal liver function (hepatic enzymes more than 3 times the upper normal limits)
- Any clinically meaningful unstable renal, hepatic, cardiovascular, respiratory, cerebrovascular disease or other serious, progressive physical disease.
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: 55 Years
Clinical Trial Sponsor Information
Lead Sponsor: University of Montreal
Overall Clinical Trial Officials and Contacts
Emmanuel Stip, Md, MSc, CSPQ Principal Investigator Centre de recherche Fernand-Seguin, Hôpital Louis-H Lafontaine, Departement of Psychiatry, Faculty of medicine, University of Montreal
Additional Information
Information obtained from ClinicalTrials.gov on August 29, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00295412
Study ID Number: 5077-99904
ClinicalTrials.gov Identifier: NCT00295412
Health Authority: Canada: Health Canada
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
